Literature DB >> 7888152

Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics.

H M Wisniewski1, J Constantinidis, J Wegiel, M Bobinski, M Tarnawski.   

Abstract

The clinical histories of 102 schizophrenics who died at 70 years of age or older were reviewed. The incidence of neurofibrillary tangles (NFTs) was two times higher in the patients who received (74%) than in those who did not receive (36%) treatment with neuroleptics. The development of NFTs started earlier in the treated group. Further studies comparing brains of nine schizophrenics (average age, 86 years) who did not receive treatment with neuroleptics and seven age-matched cases who received neuroleptics, both with neurofibrillary pathology and neuritic plaques, showed characteristic differences. The numerical density of NFTs was slightly greater in the cornu Ammonis (CA1 and CA2) and subiculum of treated patients. Significantly lower numerical density and lower percentage of pretangles (stage 0) and early and mature tangles (stages 1 and 2) and increased number of end-stage tangles (stage 3) were found in the CA, subicular complex, and cerebral cortex of the treated group. These changes suggest accelerated neurofibrillary degeneration in neurons. A significant increase in the numerical density of tau-1-positive plaques was observed in sector CA1 of the CA (from 0.15/mm2 to 17.36/mm2), subiculum (from 0/mm2 to 16.62/mm2), temporal cortex (from 0.14/mm2 to 9.46/mm2), and occipital cortex (from 0.08/mm2 to 0.39/mm2). The higher numerical density of tau-1-positive plaques, but not of 4G8-positive plaques, indicates acceleration of neurofibrillary changes in the plaques of patients treated with neuroleptics. The significant decrease (20-25%) in the numerical density of neurons in the pyramidal layer of sectors 2-4 in the CA appears to be associated with accelerated neurofibrillary changes in neurons and plaques in the treated group. This study demonstrates that chronic treatment with neuroleptics--not schizophrenia itself--significantly increases the risk of more frequent, earlier, and accelerated development of neurofibrillary pathology in the brains of elderly schizophrenics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888152     DOI: 10.1097/00002093-199408040-00001

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  6 in total

Review 1.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 2.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

3.  Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

Authors:  Allyson V McCormick; Jeanna M Wheeler; Chris R Guthrie; Nicole F Liachko; Brian C Kraemer
Journal:  Biol Psychiatry       Date:  2012-11-07       Impact factor: 13.382

Review 4.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

Review 5.  What happens in the brain of schizophrenia patients?: an investigation from the viewpoint of neuropathology.

Authors:  Shuji Iritani
Journal:  Nagoya J Med Sci       Date:  2013-02       Impact factor: 1.131

Review 6.  mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Authors:  Larisa Ryskalin; Fiona Limanaqi; Alessandro Frati; Carla L Busceti; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.